← All trials
NCT03459911
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 8, 2018
- Primary completion
- Mar 11, 2018
- Completion date
- Jun 5, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 66
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Pharmtechnology LLCLead sponsor
- Reliance Life Sciences Pvt. LtdCollaborator
- Reliance Life Sciences Pvt. LtdOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.